Rigel Pharmaceuticals Announces Employee Inducement Grants Under NASDAQ Rule 5635(c)(4)

Rigel Pharmaceuticals Announces Inducement Grants

Rigel Pharmaceuticals, Inc., listed on NASDAQ under the ticker RIGL, has made a significant announcement regarding employee incentives. On October 3, 2025, the company revealed that it had granted awards in accordance with NASDAQ Listing Rule 5635(c)(4) as part of its Inducement Plan. This strategic move is designed to attract talent and foster commitment among new hires.

The board’s Compensation Committee sanctioned this initiative, which includes the issuance of 41,138 stock options alongside 27,475 restricted stock units, distributed among 14 non-executive employees. The terms of the grant stipulate that these awards will vest over four years, featuring a one-year cliff before any stock options or units may vest. This structure not only incentivizes employees to join Rigel but also encourages them to remain with the company for a substantial period, promoting stability and continuity within the workforce.

About Rigel Pharmaceuticals

Founded in 1996 and based in South San Francisco, California, Rigel Pharmaceuticals is a biotechnology firm focused on pioneering innovative therapies aimed at treating hematologic disorders and various forms of cancer. The company is committed to improving patient outcomes through the discovery and development of novel therapeutic options. As it stands, Rigel is actively working on both marketed products and an extensive pipeline of potential therapies that have the capacity to significantly enhance the lives of patients afflicted by serious health conditions.

In addition to its recent grant announcements, Rigel maintains a strong presence in the biotechnology sector, frequently engaging with investors and stakeholders to keep them informed on company developments. For those interested in learning further about Rigel’s ongoing innovations or its existing product offerings, additional information is readily available on the official website at www.rigel.com.

This recent employee grant is anticipated to bolster Rigel’s workforce quality, positioning the firm for ongoing success as it navigates the complexities of the biotech landscape. With employee satisfaction and retention being critical elements in the competitive biotechnology arena, Rigel’s proactive measures could yield beneficial results for the company’s future endeavors.

For more details related to investor relations or any media inquiries, interested parties may reach out to Rigel Pharmaceuticals directly at the contact information provided on their website. The firm remains dedicated to maintaining transparency and fostering relationships with both its employees and investors alike.

As Rigel Pharmaceuticals continues its journey in the biotechnology space, initiatives like these play a pivotal role in attracting skilled professionals who are essential to driving forward the company’s mission of therapeutic advancement.